In lower-risk patients, the CoreValve transcatheter aortic valve replacement (TAVR) device beat surgery when it came to patient survival, found a subanalysis of the pivotal trial that led to approval for high-risk patients.
In lower-risk patients, the CoreValve transcatheter aortic valve replacement (TAVR) device beat surgery when it came to patient survival, found a subanalysis of the pivotal trial that led to approval for high-risk patients.